This task order is designed to determine the relative effectiveness (as cancer chemopreventive agents) of EGFr, MEK, and PI3K inhibitors administered on various schedules. This information will be used as a guide in designing clinical trials of these agents.

Agency
National Institute of Health (NIH)
Type
Station Support Contracts (N03)
Project #
261201200013I-0-26100007-2
Application #
8744466
Study Section
Project Start
2013-09-19
Project End
2015-09-18
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$647,739
Indirect Cost